Boehringer Ingelheim
Pays vs peer median
×1.15
+15% premium
Sample
13
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.15 | 9 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 3 | ×0.87 | 4 |
| approved | ×1.50 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | CD73-101 | Nektar Therapeutics | DLBCL | phase_3 | $925M | $6.7B |
| 2026 | SIRPα-mab | Junshi Biosciences | Cervical | approved | $3.7B | $16.4B |
| 2025 | MUC16-tinib | BioNTech | Sarcoma | discovery | $22M | $333M |
| 2025 | ATR-201 | Mirati Therapeutics | Prostate | approved | $1.8B | $6.3B |
| 2025 | CD38-mab | G1 Therapeutics | GBM | discovery | $30M | $610M |
| 2025 | Anti-B7-H4-201 | Elevation Oncology | Gastric | phase_3 | $898M | $4.5B |
| 2025 | VEGFR-tinib | Zai Lab | Follicular Lymphoma | approved | $1.9B | $8.3B |
| 2025 | VEGFR-201 | Agenus | ALL | phase_3 | $983M | $5.9B |
| 2025 | Nectin-4-301 | Arcus Biosciences | Prostate | phase_3 | $964M | $5.2B |
| 2025 | KRAS G12C | Affimed | T-cell Lymphoma | preclinical | $82M | $675M |
| 2025 | Anti-CEA-tinib | Monte Rosa Therapeutics | AML | phase_3 | $260M | $2.0B |
| 2024 | Ochre RNA program | Ochre Bio | MASH/NASH | preclinical | $35M | $1.3B |
| 2024 | ICOS-201 | Allogene Therapeutics | Mantle Cell Lymphoma | phase_2 | $582M | $4.6B |
| 2024 | checkpoint_inhibitor | Nerio Therapeutics | checkpoint_inhibitor | preclinical | $1.3B | $1.3B |
| 2024 | SZN-413 (Wnt modulator for retina) | Surrozen | Diabetic retinopathy, DME | preclinical | $40M | $599M |
How this is computed
For each Boehringer Ingelheim deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 13 disclosed deal premiums vs. peer medians. Raw premium 1.147, clamped to [0.7, 1.5].